Clinical Trial Update: A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating different doses of BI 836880 in combination with Ezabenlimab in patients with advanced non-small cell lung cancer; results completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BI 836880
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2025-11-10